| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Collegium Pharmaceutical (NASDAQ:COLL) reported its Q4 earnings results on Thursday, February 22, 2024 at 04:10 PM.
Here's what investors need to know about the announcement.
Collegium Pharmaceutical beat estimated earnings by 139.39%, reporting an EPS of $1.58 versus an estimate of $0.66.
Revenue was up $20.12 million from the same period last year.
Last quarter the company beat on EPS by $0.82 which was followed by a 6.6% increase in the share price the next day.
Here's a look at Collegium Pharmaceutical's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | 0.52 | 1.22 | 0.31 | -0.14 |
| EPS Actual | 1.34 | 1.26 | 1.32 | 1.09 |
| Revenue Estimate | 138.53M | 137.98M | 138.47M | 125.19M |
| Revenue Actual | 136.71M | 135.55M | 144.77M | 129.62M |
To track all earnings releases for Collegium Pharmaceutical visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: COLL
